EVALUATION OF PATIENT AND PUBLIC INVOLVEMENT INITIATIVES IN HEALTH TECHNOLOGY ASSESSMENT: A SURVEY OF INTERNATIONAL AGENCIES

被引:34
|
作者
Weeks, Laura [1 ]
Polisena, Julie [1 ]
Scott, Anna Mae [2 ]
Holtorf, Anke-Peggy [3 ]
Staniszewska, Sophie [4 ]
Facey, Karen [5 ]
机构
[1] Canadian Agcy Drugs & Technol Hlth CADTH, Ottawa, ON, Canada
[2] Bond Univ, Ctr Res Evidence Based Practice, Southport, Qld, Australia
[3] Hlth Outcomes Strategies GmbH, Basel, Switzerland
[4] Univ Warwick, Coventry, W Midlands, England
[5] Univ Edinburgh, Edinburgh, Midlothian, Scotland
关键词
Patient involvement; Public involvement; Evaluation; PERSPECTIVES; DECISIONS; CONSUMERS; IMPACT; POLICY;
D O I
10.1017/S0266462317000976
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Although there is increased awareness of patient and public involvement (PPI) among health technology assessment (HTA) organizations, evaluations of PPI initiatives are relatively scarce. Our objective as members of Health Technology Assessment International's (HTAi's) Patient and Citizen Involvement Group (PCIG) was to advance understanding of the range of evaluation strategies adopted by HTA organizations and their potential usefulness. Methods: In March 2016, a survey was sent to fifty-four HTA organizations through the International Network of Agencies for Health Technology Assessment (INAHTA) and contacts of members of HTAi's PCIG. Respondents were asked about their organizational structure; how patients and members of the public are involved; whether and how PPI initiatives have been evaluated, and, if so, which facilitators and challenges to evaluation were found and how results were used and disseminated. Results: Fifteen (n = 15) programs from twelve countries responded (response rate 27.8 percent) that involved patients (14/15) and members of the public (10/15) in HTA activities. Seven programs evaluated their PPI activities, including participant satisfaction (5/7), process (5/7) and impact evaluations (4/7). Evaluation results were used to improve PPI activities, identify education and training needs, and direct strategic priorities. Facilitators and challenges revolved around the need for stakeholder buy-in, sufficient resources, senior leadership, and including patients in evaluations. Conclusions: A small but diverse set of HTA organizations evaluate their PPI activities using a range of strategies that reflect the range of rationales and approaches to PPI in HTA. It will be important for HTA organizations to draw on evaluation theories and methods.
引用
收藏
页码:715 / 723
页数:9
相关论文
共 50 条
  • [31] History of the international societies in health technology assessment: International Society for Technology Assessment in Health Care and Health Technology Assessment International
    Banta, David
    Jonsson, Egon
    Childs, Paul
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 : 19 - 23
  • [32] HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES: A SURVEY OF NON-EUROPEAN UNION AGENCIES
    Ciani, Oriana
    Wilcher, Britni
    Blankart, Carl Rudolf
    Hatz, Maximilian
    Rupel, Valentina Prevolnik
    Erker, Renata Slabe
    Varabyova, Yauheniya
    Taylor, Rod S.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2015, 31 (03) : 154 - 165
  • [33] Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies
    Egilman, Alexander C.
    Wallach, Joshua D.
    Dhruva, Sanket S.
    Gonsalves, Gregg S.
    Ross, Joseph S.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2019, 34 (11) : 2319 - 2321
  • [34] Methods of international health technology assessment agencies for economic evaluations- a comparative analysis
    Tim Mathes
    Esther Jacobs
    Jana-Carina Morfeld
    Dawid Pieper
    BMC Health Services Research, 13
  • [35] Methods of international health technology assessment agencies for economic evaluations- a comparative analysis
    Mathes, Tim
    Jacobs, Esther
    Morfeld, Jana-Carina
    Pieper, Dawid
    BMC HEALTH SERVICES RESEARCH, 2013, 13
  • [36] Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies
    Alexander C. Egilman
    Joshua D. Wallach
    Sanket S. Dhruva
    Gregg S. Gonsalves
    Joseph S. Ross
    Journal of General Internal Medicine, 2019, 34 : 2319 - 2321
  • [37] Value and Implementation of Patient and Public Involvement and Engagement in Health Technology Assessment for Japan: implications from systematic searches
    Kaneyasu, Takako
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2025, 41 (01)
  • [38] Evaluation of pharmaceutical risk by public health agencies
    Imbs, JL
    ETHICAL DIMENSION OF STRATEGIES USED BY DRUG COMPANIES, 1996, : 73 - 77
  • [39] DIGITAL HEALTH INTERVENTIONS: A REVIEW OF ECONOMIC EVALUATION GUIDELINES FROM HEALTH TECHNOLOGY ASSESSMENT AGENCIES
    Zhou, A.
    Yi, Y.
    VALUE IN HEALTH, 2022, 25 (12) : S301 - S302
  • [40] Joint project of the International Network of Agencies for Health Technology Assessment -: Part 2:: Managing the diffusion of positron emission tomography with health technology assessment
    Adams, EJ
    Almazán, C
    Morland, B
    Bradbury, I
    King, R
    Rheinberger, P
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2006, 22 (02) : 149 - 154